IPO - EBR Systems Inc. - 24 November 2021 11:00AM AEDT ##, page-50

EBR did well considering:

"Radiopharm Theranostics tanks on ASX debut
Shares in Paul Hopper’s Radiopharm Theranostics shed more than 33 per cent of their IPO value on their ASX debut on Thursday.
Radiopharm has joined a list of other IPO first-day flops: a week ago biopharmaceutical company Tissue Repair had no demand, and it fell about 40 per cent on its debut.
Radiopharm is one of 121 companies to have made their debut on the sharemarket this year – the most since the 136 listings of 2007, according to data from Refinitiv. But not all listings go as planned. Radiopharm raised $50 million at 60¢ a share as part of its float, valuing the company at $152 million. But the stock swiftly went south as it began trading on Thursday and never recovered. The shares ended the day at just 40¢ apiece.The paper value of chairman Mr Hopper’s 35.5 per cent stake fell from $54 million to $36 million in just a few hours.
The early stage company does not have revenue from licence arrangements or product sales. It is developing a platform of radiopharmaceutical products for diagnostic and therapeutic cancer treatment.
The chief executive of ASX-listed Imugene, Leslie Chong, and other Imugene supporters are also backing the company, including Emma & Tom’s co-founder Emma Welsh and cattleman Jack Mann (who owns more than 5 per cent of Imugene). Others to buy into the float include CHAMP Ventures’ Su-Ming Wong, fashion designer and Celebrity MasterChef contestant Collette Dinnigan and Shark Tank’s Andrew Banks.Biotech entrepreneur Mr Hopper, who was unavailable for comment on Thursday, is also executive chairman and founder of Imugene and Chimeric Therapeutics, and the former chairman of Viralytics, which was acquired by Merck in 2018 for $502 million.
Tamim Asset Management head of Australian equities Ron Shamgar asked if Radiopharm was competing against Tissue Repair for the worst IPO of all time.“Seems to me most of these IPOs went to flippers rather than investors who are actually interested in their products,” he tweeted. Another Tweet came from @AKIntelilnv who said: “As expected $RAD also flopped. Greedy IPO raise was meant to flop. Should recover from there after all pre-IPO holders will sell all holdings. Still a good company but raise was too much.” "